Physician profile
Todd T Brown
NPI 1780642264
$143,040.01
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $13K · 2021: $5,380 · 2022: $37K · 2023: $31K · 2024: $7,609 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Travel and Lodging: $1,337 · Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,396.45 |
| Travel and Lodging | $1,336.69 |
| Food and Beverage | $965.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $78,792.44 | 2019-2025 | Cabenuva |
| Merck Sharp & Dohme LLC | $35,936.04 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $9,413.93 | 2020-2024 | Symtuza |
| Janssen Products, LP | $7,525.00 | 2022 | |
| Theratechnologies INC. | $5,248.88 | 2019 | |
| Gilead Sciences, INC. | $4,595.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,000.00 | 2019-2020 | |
| Emd Serono, INC. | $528.50 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.